| Killing mechanisms of chimeric antigen receptor (CAR) T cells MR Benmebarek, CH Karches, BL Cadilha, S Lesch, S Endres, S Kobold International journal of molecular sciences 20 (6), 1283, 2019 | 421 | 2019 |
| CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment M Di Pilato, R Kfuri-Rubens, JN Pruessmann, AJ Ozga, M Messemaker, ... Cell 184 (17), 4512-4530. e22, 2021 | 231 | 2021 |
| Limitations in the design of chimeric antigen receptors for cancer therapy S Stoiber, BL Cadilha, MR Benmebarek, S Lesch, S Endres, S Kobold Cells 8 (5), 472, 2019 | 164 | 2019 |
| T cells armed with CXC chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours S Lesch, V Blumenberg, S Stoiber, A Gottschlich, J Ogonek, BL Cadilha, ... Nature biomedical engineering 5 (11), 1246-1260, 2021 | 104 | 2021 |
| EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells S Kailayangiri, B Altvater, S Lesch, S Balbach, C Göttlich, J Kühnemundt, ... Molecular Therapy 27 (5), 933-946, 2019 | 83 | 2019 |
| Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors BL Cadilha, MR Benmebarek, K Dorman, A Oner, T Lorenzini, H Obeck, ... Science advances 7 (24), eabi5781, 2021 | 75 | 2021 |
| Determinants of response and resistance to CAR T cell therapy S Lesch, MR Benmebarek, BL Cadilha, S Stoiber, M Subklewe, S Endres, ... Seminars in Cancer Biology 65, 80-90, 2020 | 70 | 2020 |
| Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy CH Karches, MR Benmebarek, ML Schmidbauer, M Kurzay, R Klaus, ... Clinical Cancer Research 25 (19), 5890-5900, 2019 | 37 | 2019 |
| The promise and perils of immunotherapy S Lesch, S Gill Blood Advances 5 (18), 3709-3725, 2021 | 33 | 2021 |
| Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia A Gottschlich, M Thomas, R Grünmeier, S Lesch, L Rohrbacher, V Igl, ... Nature biotechnology 41 (11), 1618-1632, 2023 | 29 | 2023 |
| A modular and controllable T cell therapy platform for acute myeloid leukemia MR Benmebarek, BL Cadilha, M Herrmann, S Lesch, S Schmitt, S Stoiber, ... Leukemia 35 (8), 2243-2257, 2021 | 27 | 2021 |
| Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy N Wellhausen, RP O’Connell, S Lesch, NW Engel, AK Rennels, ... Science translational medicine 15 (714), eadi1145, 2023 | 26 | 2023 |
| Epitope editing in hematopoietic cells enables CD45-directed immune therapy N Wellhausen, AK Rennels, S Lesch, S Agarwal, B Charria, G Choi, ... Blood 140 (Supplement 1), 862-864, 2022 | 8 | 2022 |
| PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models S Lesch, A Nottebrock, F Rataj, C Heise, S Endres, S Kobold Cellular Oncology 46 (1), 227-235, 2023 | 6 | 2023 |
| PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells SB Lacher, J Dörr, GP de Almeida, J Hönninger, F Bayerl, A Hirschberger, ... Nature, 1-9, 2024 | 3 | 2024 |
| Arming T cells with CXC-motive receptor 6 enables adoptive T cell therapy of pancreatic cancer S Lesch, V Blumenberg, S Stoiber, J Ogonek, B Cadilha, Z Dantes, ... European Journal of Cancer 110, S25-S26, 2019 | 2 | 2019 |
| 10.01 Prostanoid-insensitive chimeric antigen receptor modified T cells mediate therapeutic efficacy in solid cancer models J Dörr, L Gregor, SB Lacher, A Öner, S Lesch, S Michaelides, L Majed, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 1), 2024 | | 2024 |
| Single sequencing-based development of chimeric antigen receptor (CAR) T cells for the treatment of acute myeloid leukemias A Gottschlich, M Thomas, R Grunmeier, S Lesch, LIV Rohrbacher, ... ONCOLOGY RESEARCH AND TREATMENT 45 (SUPPL 2), 170-170, 2022 | | 2022 |
| P09. 01 Single-cell transcriptomic atlas-guided development of chimeric antigen-receptor (CAR) T cells for the treatment of acute myeloid leukemia A Gottschlich, M Thomas, R Grünmeier, S Lesch, L Rohrbacher, V Igl, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 1), 2022 | | 2022 |
| P07. 01 A modular and controllable T cell therapy platform for AML M Benmebarek, BL Cadilha, M Herrmann, S Schmitt, S Lesch, S Stoiber, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 1), 2021 | | 2021 |
